Sensata Technologies (NYSE:ST) reported quarterly earnings of $0.85 per share which met the analyst consensus estimate. This is a 2.3 percent decrease over earnings of $0.87 per share from the same period last year. The company reported quarterly sales of $1.02 billion which beat the analyst consensus estimate of $1.01 billion by 0.79 percent. This is a 7.04 percent increase over sales of $951.02 million the same period last year.
Why Is Inflammation Disease-Focused Celldex Therapeutics Stock Trading Higher Today?
Celldex Therapeutics Inc (NASDAQ: CLDX) released topline results from its Phase 2 trial of barzolvolimab in patients with moderate to severe chronic spontaneous urticaria (CSU) refractory to antihistamines, including patients
